IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IKS-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IKS-03 overview

IKS-03 (LCB-73, NI-2201) is under development for the treatment of acute lymphocytic leukemia, Burkitt lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma and b-cell non-Hodgkin lymphoma. It acts by targeting CD19. The therapeutic candidate is an antibody-drug conjugate (ADC). It is being developed based on ConjuALL platform technology. It is administered through intravenous route.

Iksuda Therapeutics overview

Iksuda Therapeutics (Iksuda) is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprietary linker and stable glycan technologies permalink and premacarb to deliver solutions for development and manufacture efficacious and safe biologics to improve half-life and optimize bio-availability. Iksuda is headquartered in Newcastle upon Tyne, Tyne and Wear, the UK.

For a complete picture of IKS-03’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.